Optimize Your Prediction, Measurement & Modulation of Gene Therapy Immunogenicity to Guarantee the Safety of the Next Generation of Clinical Candidates

The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate.

In the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on the latest approaches to predict, measure and overcome every immunogenicity challenge you encounter.

Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays.

Incorporating insights from leading immunological, bioanalytical and translational experts, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity.

View the full event guide now for full meeting details!

What Will You Learn?

Favicon GTx Immunogenicity

How Chameleon Bioscience are developing an immune evasive AAV for repeat dosing

Favicon GTx Immunogenicity

The impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon

Favicon GTx Immunogenicity

Strategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics

Favicon GTx Immunogenicity

Performances of biosafety analytical assays commonly used in gene therapy development

Favicon GTx Immunogenicity

Immunogenicity risk assessment for AAV-based gene therapies with Roche

Favicon GTx Immunogenicity

How to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis

Favicon GTx Immunogenicity

Regulatory considerations for immune responses to gene therapies with the FDA

Who Will You Meet?

gtxi companies (10)

Previous Gene Therapy Immunogenicity Attendees Have Said

 Inspiring virtual meeting allowing efficient learning about the most recent advances in gene therapy immunogenicity while still having interactions with peers.”
Roche, 2020 Attendee

 

“Excellent overview of the current understanding of AAV immunogenicity and new directions to mitigate it.”
REGENXBIO, 2020 Attendee

 

“It was great to have a conference focused on analytical challenges for testing immune markers and modulating immune responses to gene therapies.”
Kriya Therapeutics, 2020 Attendee

 

“I got a lot out of the interactive and exciting scientific discussions after each session.”
Indiana University School of Medicine, 2020 Attendee

Other Events in the Gene Therapy Series